Appropriate use of PCSK9 Inhibitors in India

J Assoc Physicians India. 2019 Apr;67(4):74-85.

Abstract

The burden of atherosclerotic cardiovascular (CV) disease is alarmingly high and increasing in our country. Dyslipidemia is one of the major modifiable risk factors, and INTERHEART study showed that dyslipidemia had the highest population attributable risk for myocardial infarction. In the management of dyslipidemia, low-density lipoprotein cholesterol (LDL-C) is the primary therapeutic target. In addition to therapeutic lifestyle changes, statins and ezetimibe effectively lower LDL-C and consequently improve CV outcomes. However, there are situations where these drugs fall short of achieving the target or they may not be well tolerated.

MeSH terms

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Enzyme Inhibitors / therapeutic use*
  • India
  • PCSK9 Inhibitors*
  • Proprotein Convertase 9 / metabolism

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Enzyme Inhibitors
  • PCSK9 Inhibitors
  • PCSK9 protein, human
  • Proprotein Convertase 9